Merck's Tulisokibart Hits Key Goals in Phase 3 Ulcerative Colitis Study

Merck & Co. said a late-stage study of its autoimmune drug candidate tulisokibart in ulcerative colitis hit its key goals. Merck on Monday said the Phase 3 induction-only study met its primary ...

Merck KGaA: Bio-Techne Acquisition Improves Quality, But The Stock Seems Fully Valued (Downgrade)

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.
Fierce Biotech

Merck KGaA pledges $50M to build new cardio biotech with eye to later acquisition

The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...
GEN - Genetic Engineering and Biotechnology News

Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments

Merck & Co. will partner with Protillion Biosciences to discover multiple new therapy candidates, through a collaboration ...

Here’s Why Merck (MRK) is Among the 10 Undervalued Counter Cyclical Stocks to Buy Now

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now.
Seeking Alpha

Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise

Over the past twelve months, the stock of New Jersey-headquartered Pharma giant Merck & Co., Inc. (MRK) has quietly increased by a sector-leading 55%. However, on a three-year basis, its stock is up ...
FiercePharma

Merck nabs $30M grant commitment from Delaware as state looks to entice Big Pharma investment

Should a plan come to fruition in Delaware, Merck would invest around $900 million in a new, 450,000-square-foot facility, local news outlets reported this week ...

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.